Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MESO | PRESS-RELEASE | bullish | 7/10 | Mesoblast highlighted its commercial strategy as Ryoncil® nears $100M in net revenue since launch, announced the close o | Apr 8, 2026 |
| CUE | PRESS-RELEASE | bullish | 6/10 | Cue Biopharma announced it will receive a $7.5 million preclinical milestone payment from Boehringer Ingelheim in May 20 | Apr 8, 2026 |
| ASND | PRESS-RELEASE | bullish | 8/10 | Ascendis Pharma announced Week 52 data from its Phase 2 COACH trial showing that the combination of TransCon CNP and Tra | Apr 8, 2026 |
| NAMS | PRESS-RELEASE | neutral | 5/10 | { "summary": "NewAmsterdam Pharma issued a press release announcing participation in an upcoming investor conference, | Apr 8, 2026 |
| AXSM | PRESS-RELEASE | neutral | 1/10 | Axsome Therapeutics, Inc. announced it will report its Q1 2026 results on May 4. | Apr 8, 2026 |
| RADX | PRESS-RELEASE | bullish | 7/10 | Radiopharm Theranostics announced a positive safety review by the Data Safety and Monitoring Committee, allowing advance | Apr 8, 2026 |
| ANIP | PRESS-RELEASE | bullish | 7/10 | ANI Pharmaceuticals announced FDA approval and immediate launch of Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg, t | Apr 8, 2026 |
| ATAI | PRESS-RELEASE | bullish | 8/10 | AtaiBeckley announced positive Phase 2a results for BPL-003 in treatment-resistant depression, showing a 66.7% antidepre | Apr 8, 2026 |
| NRIX | PRESS-RELEASE | bearish | 7/10 | Nurix Therapeutics (NRIX) reported Q1 2026 financial results with revenue of $6.3M, down 66% YoY, and a net loss of $87. | Apr 21, 2026 |
| NBP | PRESS-RELEASE | bullish | 8/10 | NovaBridge Biosciences reported a net loss of $46.3M for FY 2025 with EPS of $(0.21), a significant improvement from $(0 | Apr 7, 2026 |
| AMRX | PRESS-RELEASE | neutral | 1/10 | Amneal Pharmaceuticals LLC announced it will report its Q1 2026 results on May 1, 2026. | Apr 7, 2026 |
| COEP | PRESS-RELEASE | mixed | 6/10 | Coeptis Therapeutics announced that Nasdaq has approved the listing of the post-merger company's common stock under the | Apr 7, 2026 |
| VVOS | PRESS-RELEASE | neutral | 5/10 | Vivos Therapeutics closed a $2.25 million private placement with V-Co Investors 3 LLC, an affiliate of New Seneca Partne | Apr 7, 2026 |
| XENE | PRESS-RELEASE | bearish | 5/10 | Xenon Pharmaceuticals (XENE) reported a Q4 2025 earnings miss with EPS of -$1.31 versus consensus of -$1.20, a 9.4% nega | Apr 7, 2026 |
| EVAX | PRESS-RELEASE | bullish | 7/10 | Evaxion announced the successful completion of the one-year extension of its phase 2 trial for its personalized cancer v | Apr 7, 2026 |
| IVVD | PRESS-RELEASE | neutral | 3/10 | Invivyd launched a national education campaign called 'Antibodies for Any Body' in partnership with ski champion Lindsey | Apr 7, 2026 |
| ACIU | PRESS-RELEASE | bullish | 6/10 | AC Immune announced an amendment to its collaboration agreement with Eli Lilly to continue developing Tau-targeting smal | Apr 7, 2026 |
| FENC | PRESS-RELEASE | neutral | 4/10 | Fennec Pharmaceuticals announced the initiation of an investigator-sponsored Phase I/II study at the University of Arizo | Apr 7, 2026 |
| OKYO | PRESS-RELEASE | neutral | 4/10 | OKYO Pharma announced a Scientific Advisory Board meeting and upcoming data presentation at ASCRS 2026, highlighting Pha | Apr 7, 2026 |
| ANIP | PRESS-RELEASE | neutral | 4/10 | ANI Pharmaceuticals announced the publication of NEW DAY clinical trial results for ILUVIEN in the journal Ophthalmology | Apr 7, 2026 |
| CLDX | PRESS-RELEASE | neutral | 5/10 | Celldex Therapeutics closed an underwritten public offering of 11.9 million shares at $29.00 per share, raising approxim | Apr 6, 2026 |
| ONMD | PRESS-RELEASE | bullish | 8/10 | OneMedNet reported strong 2025 financial results with Real-World Data (RWD) revenue surging 329% year-over-year to $1.25 | Apr 6, 2026 |
| AKTX | PRESS-RELEASE | neutral | 4/10 | Akari Therapeutics announced a strategic partnership with WuXi XDC to accelerate the development of its novel PH1 payloa | Apr 6, 2026 |
| PRAX | PRESS-RELEASE | bullish | 8/10 | Praxis Precision Medicines announced positive topline results from the EMBRAVE Part A trial of elsunersen in pediatric p | Apr 6, 2026 |
| MDCX | PRESS-RELEASE | neutral | 4/10 | Medicus Pharma announced the submission of an optimized Phase 2 clinical trial design for Teverelix, its investigational | Apr 6, 2026 |
| ORGO | PRESS-RELEASE | neutral | 1/10 | Organogenesis Holdings Inc. announced it will report its fiscal Q1 2026 results on May 7, 2026. | Apr 6, 2026 |
| ELAB | PRESS-RELEASE | mixed | 5/10 | PMGC Holdings Inc. (ELAB) announced that its subsidiary NorthStrive Defense Tech has secured an exclusive option to lice | Apr 6, 2026 |
| AGIO | PRESS-RELEASE | neutral | 1/10 | Agios Pharmaceuticals, Inc. announced it will host a conference call on April 29 to discuss its Q1 2026 results. | Apr 6, 2026 |
| LYB | PRESS-RELEASE | neutral | 1/10 | LyondellBasell announced it will report its Q1 results on May 1, 2026. | Apr 6, 2026 |
| ORIC | PRESS-RELEASE | neutral | 2/10 | ORIC Pharmaceuticals announced the grant of stock options and restricted stock units to a new non-executive employee as | Apr 3, 2026 |